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A consistent feature of varicella-zoster virus (VZV) latency is the restricted pattern of viral gene expression
in human ganglionic tissues. To understand further the significance of this gene restriction, we used in situ
hybridization (ISH) to detect the frequency of RNA expression for nine VZV genes in trigeminal ganglia (TG)
from 35 human subjects, including 18 who were human immunodeficiency virus (HIV) positive. RNA for VZV
gene 21 was detected in 7 of 11 normal and 6 of 10 HIV-positive subjects, RNA for gene 29 was detected in 5
of 14 normal and 11 of 11 HIV-positive subjects, RNA for gene 62 was detected in 4 of 10 normal and 6 of 9
HIV-positive subjects, and RNA for gene 63 was detected in 8 of 17 normal and 12 of 15 HIV-positive subjects.
RNA for VZV gene 4 was detected in 2 of 13 normal and 4 of 9 HIV-positive subjects, and RNA for gene 18 was
detected in 4 of 15 normal and 5 of 15 HIV-positive subjects. By contrast, RNAs for VZV genes 28, 40, and 61
were rarely or never detected. In addition, immunocytochemical analysis detected the presence of VZV gene
63-encoded protein in five normal and four HIV-positive subjects. VZV RNA was also analyzed in explanted
fresh human TG and dorsal root ganglia from five normal human subjects over a period of up to 11 days in
culture. We found a very different pattern of gene expression in these explants, with transcripts for VZV genes
18, 28, 29, 40, and 63 all frequently detected, presumably as a result of viral reactivation. Taken together, these
data provide further support for the notion of significant and restricted viral gene expression in VZV latency.
Several laboratories over the last decade have used in situ
hybridization (ISH) and/or PCR amplification in attempts to
define unambiguously the physical state of latent varicella-
zoster virus (VZV), including the cell type specificity of latent
virus, since this has important implications for viral neuro-
pathogenesis (8, 18). The cell type specificity of latent VZV
had been controversial for many years, with some investigators
reporting an exclusively neuronal location (7, 9) and others
reporting a nonneuronal site (5, 19), while latent VZV had also
been reported to be present in both neuronal and satellite cells
(15). Clarification of this issue was provided by two recent
studies, one of which used ISH and PCR amplification to show
that latent VZV in human trigeminal ganglia (TG) was located
predominantly in neurons with only occasional satellite cells
infected (12), while the other used a dissociated cell technique
using neuronal and nonneuronal TG cell fractions to indicate
that latent VZV DNA is present primarily, if not exclusively, in
neurons (14). A further study demonstrated that, as expected,
more than one region of the VZV genome is present in neu-
rons during latency in dorsal root ganglia (DRG) and that both
a VZV gene and its corresponding RNA transcript can be
present in serial sections in the same region of the ganglion
(13).
Transcription during latency of several VZV genes, includ-
ing genes 21, 29, 62, and 63, has been reported by several
groups (1–4, 13, 19), and there is also weaker evidence for
transcription of gene 4 and other genes (5, 18, 19). By contrast,
the only herpes simplex virus (HSV) transcripts which have
been detected are the latency-associated transcripts (21). The
significance of the apparently highly restricted pattern of VZV
gene expression during latency is not known. There is also
some evidence for VZV protein expression in ganglionic tis-
sues during latency in that VZV gene 63-encoded protein has
been reported to be expressed in the cytoplasm of neurons in
latently infected ganglia (17), and a recent study has also re-
ported the presence in normal ganglia of proteins encoded by
all of the VZV genes which are expressed during latency (16).
A major theoretical problem with these RNA detection
studies of latently infected human ganglia is that VZV may
have reactivated immediately after death and/or removal of
ganglionic tissue, making interpretation of putatively expressed
VZV genes very difficult. We addressed this issue in the pres-
ent study by hypothesizing that (i) truly expressed VZV genes
in ganglia should be detected more frequently than non-la-
tently associated genes, which may have been present only due
to localized viral reactivation, and (ii) the pattern of VZV
RNA expression in latently infected ganglia should be different
from that in explanted ganglia in which VZV had reactivated
in vitro. We provide evidence here that supports these two
postulates.
MATERIALS AND METHODS
Human tissue specimens. Human ganglionic autopsy tissues (TG and DRG)
were kindly donated by the Medical Research Council HIV Brain and Tissue
Bank in Edinburgh, Scotland, S. Straus and R. Kost (Bethesda, Md.), D. Gilden
(Denver, Colo.), and D. Doyle and D. Graham (Glasgow, Scotland). We studied
a total of 35 subjects (Tables 1 and 2, 18 of whom were infected with human
immunodeficiency virus (HIV) (13 with AIDS and 5 with pre-AIDS). To our
knowledge, the six subjects with unknown diagnoses in Table 1 were immuno-
competent and not HIV positive. In addition, control tissues included were
VZV-infected and uninfected CV-1 (African green monkey) cells, VZV-infected
human skin, and uninfected rat ganglia. Putative negative controls also included
two neonatal (,4-week-old) TG. Samples were fixed in formalin or paraformal-
dehyde prior to wax embedding. For studies shown in Tables 1 and 2, one
ganglion specimen from each subject was available and used. Each tissue sample
was studied at least twice for each probe in ISH assays.
Oligonucleotide probes. The probes used in this study (Table 3) included
probes for VZV genes 4, 18, 21, 28, 29, 40, 61, 62, and 63. These were chosen as
representing genes which had previously been reported to be expressed during
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VZV latency (genes 4, 21, 29, 62, and 63) as well as those which are not thought
to be expressed (genes 18, 28, 40, and 61). A probe control for human b-globin
was also used. All oligonucleotides were synthesized by Genosys UK.
ISH. ISH for VZV RNA was carried out as previously described (13). Five-
micrometer tissue sections were placed onto glass slides which had been pre-
coated with 3-aminopropyltriethoxysilane, incubated overnight at 37°C, dewaxed
in xylene, and then rehydrated through graded ethanols to diethyl pyrocarbon-
ate-treated H2O. The slides were then treated with 0.2 N HCl and proteinase K.
In the case of cultured cells, the HCl procedure was omitted. The proteinase K
was then inactivated by treatment with glycine–phosphate-buffered saline PBS,
following which the sections were acetylated in triethanolamine-acetic anhy-
dride. The sections were then dehydrated, and prehybridization was performed
for at least 2 h in buffer containing formamide, 23 SSC (13 SSC is 0.15 M NaCl
plus 0.015 M sodium citrate), 13 Denhardt’s solution, denatured salmon sperm
DNA, and yeast tRNA. Tissue sections were then hybridized overnight at 37°C
with the appropriate digoxigenin (DIG)-labeled probe in dextran sulfate prehy-
bridization buffer. Unbound probe was removed by washes with 23 SSC (twice
for 15 min each time), 13 SSC (twice for 15 min each time), and 0.13 SSC (twice
for 15 min each time) at 42°C. The resulting hybrids were detected using stan-
dard DIG reagents (Boehringer Mannheim). The slides were dipped in buffer 1
(0.1 M maleic acid, 0.15 M NaCl [pH 7.5]) and then exposed for 30 min to buffer
2 (10% DIG blocking agent). After exposure for 60 min to antibody conjugated
to alkaline phosphatase which had been diluted in buffer 2, the slides were
washed twice for 10 min each time in buffer 1. Sections were then equilibrated in
buffer 3 (100 mM Tris-HCl [pH 9.5], 100 mM NaCl, 50 mM MgCl2) and the
detection reagent (45 ml of nitroblue tetrazolium [NBT] and 35 ml of 5-bromo-
4-chloro-3-indolylphosphate [BCIP] in 10 ml of buffer 3) with levamisole (0.24
mg/ml) and left in the dark for 15 min to 2 h, until development of the purple
color. As described before (12, 13) several sections, including controls, were
processed on the same slide to avoid bias in the interpretation of color devel-
opment, and all slides were read blind.
Immunocytochemistry. The tissue sections were dewaxed, rehydrated through
graded ethanols to PBS, and then incubated for approximately 1 h in PBS
containing 1% bovine serum albumin and 1% normal sheep serum. Rabbit
polyclonal antibody (diluted 1:500) to VZV gene 63-encoded protein was a gift
from C. Sadzot and B. Rentier (6, 17). The antibody was diluted appropriately in
blocking buffer and incubated at 4°C overnight. After returning to room tem-
perature, the slides were washed three times for 5 min each in PBS and then
incubated for 1 h in a 1:300 dilution of anti-rabbit antibody (DAKO) in blocking
buffer. PBS washes were repeated as above, and the sections were incubated at
room temperature in a 1:100 dilution of streptavidin-alkaline phosphatase con-
jugate (DAKO) in blocking buffer, washed three times in PBS, and then devel-
oped using NBT-BCIP or a fuchsin kit (DAKO) containing levamisole (0.24
mg/ml) for 10 min. The slides were then washed in distilled water and mounted
using an aqueous mountant.
Explanted TG and DRG experiments. Human ganglia (TG or DRG) from
normal subjects were obtained at autopsy 14 to 48 h after death. Each ganglion
was then divided into four pieces. One piece was immediately fixed overnight in
4% paraformaldehyde or formalin, and the other three were cultivated as ex-
plants on a monolayer of CV-1 cells in RPMI 1640 containing 5% fetal calf
serum for 64 to 264 h after death, with typical sampling time points at 64, 120,
168, 192, and 264 h. Cocultivation of explanted ganglion tissues with CV-1 cells
TABLE 1. Detection by ISH of VZV RNA in normal human TGa
Patient Age Sex Diagnosis Gene 4 Gene 18 Gene 21 Gene 28 Gene 29 Gene 40 Gene 61 Gene 62 Gene 63
1 27 yr M OD 2 1 1 ND ND 2 2 1 1
2 26 yr M OD ND 1 ND ND 2 ND ND ND 1
3 26 yr M OD 2 2 1 2 1 2 ND 1 1
4 44 yr F Crohn’s disease 2 2 1 ND 2 ND ND ND 2
5 Adult ? Unknown ND 2 ND ND 1 1 ND ND 1
6 Adult ? Unknown 2 2 ND 2 2 ND ND 2 1
7 22 yr M Gunshot wound 1 2 1 ND 1 ND ND ND 1
8 Adult ? Unknown 2 2 1 2 2 ND ND 2 2
9 Adult ? Unknown ND 2 ND ND 2 ND ND ND 2
10 Adult ? Unknown 6 1 1 ND 1 ND ND ND 1
11 63 yr M Myocardial infarction ND 2 ND ND 2 ND ND ND 2
12 29 yr M Normal 2 ND 2 2 ND ND ND 2 2
13 36 yr F Asthma 2 2 2 2 ND ND ND 2 2
14 37 yr M Gunshot wound 1 1 1 ND 1 ND 2 1 1
15 Adult ? Unknown 2 2 2 2 6 2 2 2 2
16 30 yr M Gunshot wound 2 2 2 ND 2 ND ND 1 2
17 34 yr F Smoke inhalation 2 ND ND 2 2 2 ND 2 2
a M, male; F, female; ND, not determined; ?, unknown; OD, drug overdose; 1, VZV positive; 2, VZV negative; 6, equivocal result.
TABLE 2. Detection by ISH of VZV RNA in human TG from HIV-positive subjectsa
Patient Age (yr) Sex Diagnosis Gene 4 Gene 18 Gene 21 Gene 28 Gene 29 Gene 40 Gene 61 Gene 62 Gene 63
18 33 M AIDS 1 ND ND ND 1 2 ND 1 1
19 37 M AIDS ND 2 ND ND 1 ND ND ND 1
20 28 M AIDS 2 2 ND ND 1 ND ND ND 1
21 50 M AIDS 1 1 1 2 ND ND 1 1 1
22 30 M AIDS ND 2 ND ND ND ND ND ND 2
23 33 M AIDS ND 2 ND ND ND ND ND ND 2
24 38 F AIDS 1 2 2 ND 1 ND ND 1 1
25 46 M AIDS 2 2 1 2 1 2 ND 2 1
26 26 M AIDS 2 2 1 2 1 1 ND 1 1
27 27 M AIDS ND ND 2 2 ND 2 ND ND ND
28 39 M AIDS 2 2 2 2 1 2 ND 2 2
29 37 M AIDS 1 2 1 ND ND ND 2 ND 1
30 25 F AIDS ND 1 1 ND 1 ND 2 ND 1
31 29 M Pre-AIDS 2 ND 1 2 ND ND ND 2 ND
32 23 M Pre-AIDS ND 1 ND ND 1 2 2 1 1
33 29 M Pre-AIDS ND 1 ND ND ND ND ND 1 1
34 30 M Pre-AIDS ND 1 2 ND 1 2 ND ND ND
35 30 M Pre-AIDS ND 2 ND ND 1 2 ND ND 1
a M, male; F, female; ND, not determined; 1, VZV positive; 2, VZV negative.
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allowed the possible detection of infectious virus release. Ganglion tissue pieces
removed from RPMI 1640 at various time points were immediately fixed in 4%
paraformaldehyde or formalin, washed in PBS, and frozen in PBS-sucrose at
70°C until they could be wax embedded, sectioned with a microtome, and pro-
cessed for ISH as described above. All tissues from the same patient were
processed and wax embedded at the same time.
RESULTS
Frequency of RNA expression for nine VZV genes in human
TG detected by ISH. VZV RNA corresponding to nine viral
genes was examined in a total of 35 subjects (Tables 1 and 2);
of these, 17 were immunocompetent at the time of death and
18 were HIV infected. The latter were chosen because VZV
reactivation might be expected to occur more frequently in
HIV-positive individuals (12). The VZV genes studied were
chosen as representative genes spanning most of the viral ge-
nome; they included both genes which have been reported to
be expressed during VZV latency (genes 4, 21, 29, 62, and 63)
and genes which have not been previously identified as being
expressed during latency (genes 18, 28, 40, and 61). Since this
study was limited by the availability of human TG tissues, not
all genes could be examined in all cases. It can be seen from
Tables 1 and 2 that, even allowing for differences in the num-
bers of cases studied, RNA for genes 21, 29, 62, and 63 were
the most frequently detected in both the normal and HIV-
positive subjects. RNA for gene 21 was detected in 7 of 11
normal and 6 of 10 HIV-positive subjects. RNA for gene 29
was detected in 5 of 14 normal and 11 of 11 HIV-positive
subjects. RNA for gene 62 was detected in 4 of 10 normal and
6 of 9 HIV-positive subjects. RNA for gene 63 was detected in
8 of 17 normal and 12 of 15 HIV-positive subjects. By contrast,
RNA for genes 28, 40, and 61 were never or only rarely de-
tected. Thus, RNA for gene 28 was not detected in any of seven
normal or six HIV-positive subjects, RNA for gene 40 was
detected in one of five normal and one of eight HIV-positive
subjects, and RNA for gene 61 was detected in none of three
normal and one of four HIV-positive subjects. The two genes
which were detected at an intermediate frequency were genes
4 and 18. Thus, RNA for gene 4 was detected in 2 of 13 normal
and 4 of 9 HIV-positive subjects, while RNA for gene 18 was
detected in 4 of 15 normal and 5 of 15 HIV-positive subjects.
In the few cases where repeated studies gave unclear results,
an equivocal result was recorded. In both normal and HIV-
positive subjects, the VZV RNA was located predominantly in
neuronal nuclei (Fig. 1), with only occasional (,0.1%) positive
nonneuronal cells. Analysis of the HIV-positive and normal
cases (with an average neuron count of 72 cells per slide)
carried out on representative sections from several subjects
with four to six different probes showed that the proportions of
neurons which were viral RNA positive were approximately
7% for the normal and 5% for the HIV-positive cases. How-
ever, the very variable and focal distribution of the RNA-
positive neurons makes these only estimated figures. The sam-
ple size and variability did not allow formal statistical analysis
to be carried out, either for the latter cell counts or for the
relative frequencies of the different RNA-positive cases. No
RNA signal was detected in this study in the negative control
tissues such as the neonatal human TG or uninfected rat gan-
glia, while VZV-infected cells were positive (Fig. 1). To check
that cellular RNA was intact in these TG tissues, ISH was also
performed at least once for each sample with a human b-globin
probe and was found to be positive (data not shown).
Presence of VZV gene 63-encoded protein in TG neurons.
Since we had previously reported the presence of DNA for
VZV gene 63 in human TG (12), and in view of the detection
of RNA for this gene described above, as well as previous
reports of gene 63-encoded protein by others (17), we carried
out immunocytochemistry to locate this protein in both normal
and HIV-positive subjects. Only a minority of samples from
both patient groups were positive when TG sections were la-
beled with the anti-63 protein antibody (Fig. 1). Five of the
non-HIV-infected patients (patients 1, 3, 5, 14, and 16; 29%)
and four of the HIV-positive patients (patients 18, 19, 20, and
29; 22%) were positive. In all but one case (patient 16), the
gene 63-encoded protein samples had also been positive for
RNA for gene 63. Positive staining in both normal and HIV-
positive samples was detected predominantly in neurons, with
only occasional nonneuronal cells positive, as had been the
case for RNA detection. The neuronal labeling pattern was
mainly cytoplasmic and only occasionally nuclear (Fig. 1). No
labeling was detected in the negative control tissues, while the
VZV-infected skin biopsy section was positively labeled.
Temporal pattern of VZV RNA expression in explanted TG
and DRG. Having demonstrated an apparently restricted pro-
file of VZV RNA expression in a large number of fixed human
ganglia, we wondered whether this represented localized viral
reactivation or true viral gene expression in latency. We rea-
soned that a useful comparison which might shed light on this
issue would be with the temporal pattern of VZV gene expres-
sion in explanted ganglia, since the latter should be different
due to possible viral reactivation in vitro. The combined results
of this series of experiments are shown in Table 4. Fresh TG
and DRG tissues all from normal subjects were explanted as
TABLE 3. Oligonucleotide probes used in this study
VZV gene Putative or known functiona HSV-1 homolog Oligonucleotide sequence (59-39)
4 Transactivation UL54 TGCAACCTCGAAGTCACTT
ICP27
18 Ribonucleotide reductase UL40 GATTCGGACTTTCCACTTGCA
21 Unknown UL37 GGTCACTCCCACTTGTATTCC
28 DNA polymerase UL30 CGGAACTTCTTTTCCATTACAGTA
29 Major DNA binding protein UL29 TCATCTAGAATCTTTACTGCTTCTAGAGCGCCTTC
TACGGTCCAGGGCGTTTCCAGGGTTTGGATAATC
40 Major capsid protein UL19 TCTAGAAAACGCACAAAGTTTAAT
61 Transrepression ICP0 TGTGGAGAGAGGCAACTTTGC
IE110
62 Transcriptional activation ICP4 GAGTTTGTTTCGTCTTCATCCTCT
Repression IE175
63 Transcriptional activation ICP22 CGCGCTTAAGCTACACGCCATGGGGGGGCGG
Repression IE68
a See references 3, 10, and 20.
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soon as possible after death, although in these experiments
specific clinical details were not available because of ethical
and/or legal restrictions. The genes chosen were putative la-
tency associated (genes 29 and 63) and non-latency associated
(genes 18, 28, and 40). In some cases two or three ganglia were
available from the same subject (a total of 11 ganglia from five
subjects). It can be seen from Table 4 that the pattern was very
different from that seen in the 35 prefixed tissues in that all five
VZV genes studied were detected in most cases of the ex-
planted ganglia at various times in culture over a period of up
to 11 days, which was the maximum time that the tissues
remained intact. It is noteworthy that in the ganglia from
samples 1 and 2, RNAs for all genes were detected by ISH at
the earliest time points (14 to 24 h) after death of the individ-
uals. In this series of in vitro experiments, however, the vari-
ability of the assays was somewhat greater than with the fixed
ganglia, and so more equivocal results were reported. How-
ever, when VZV RNA was detected in explants, the localiza-
tion was, again, predominantly neuronal. No infectious virus
release was detected during the course of these experiments.
DISCUSSION
The increasing clinical significance of VZV infections of the
nervous system, especially in immunosuppressed patients,
makes it important to understand the molecular mechanisms
of VZV latency and reactivation (8, 11). In this study, the most
extensive of its kind to date, we provide ISH data for 35
individuals, including 18 who were HIV positive, which define
the profile of VZV gene transcription in neurons in latently
FIG. 1. (A to D) ISH of human TG with DIG-labeled probes. (A) Normal TG hybridized with VZV gene 62 probe. Several neurons are labeled. (B) Control, infant
TG hybridized with VZV gene 62 probe. No cells are labeled. (C) HIV-positive TG hybridized with VZV gene 29 probe. Several neurons are labeled. (D) Normal TG
hybridized with VZV gene 4 probe. No cells are labeled. (E) Positive control. VZV-infected skin biopsy hybridized with VZV gene probe 62. Many cells are labeled.
(F) Immunocytochemical staining of normal TG labeled with polyclonal antibody to VZV gene 63 protein. Many neurons show positive labeling. (Magnification, 3450
in all cases).
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infected TG. It was found that the most frequently detected
VZV transcripts, in both normal and HIV-positive subjects,
were those corresponding to genes 21, 29, 62, and 63. This is
consistent with previous reports which were based on much
smaller sample sizes, some of which used similar techniques
(1–4, 19). We have made the assumption that the most fre-
quently detected viral gene transcripts were the most likely to
represent truly expressed latency genes. By contrast, we rarely
or never detected RNA for VZV genes 28, 40, and 61 in either
normal or HIV-positive subjects, strongly suggesting that they
are not likely to be latency-associated genes, with their occa-
sional detection possibly representing foci of localized and
limited viral reactivation. However, in both normal and HIV-
positive subjects, we also detected an intermediate-frequency
RNA for VZV genes 4 and 18. While the former is consistent
with some (5, 13), but not all (19), previous studies and is
probably also latency associated, the finding of nine TG posi-
tive for viral RNA for gene 18 was unexpected, as it has not
been previously implicated in viral latency, although the extent
to which it has been specifically looked for is unclear. VZV
gene 18 codes for the small-unit ribonucleotide reductase
(HSV homolog UL40) (20), and we are unable at this stage to
determine the significance of this observation and whether it
represents a truly expressed latency gene or limited viral reac-
tivation in these tissues. The patterns of VZV gene expression
in the normal and HIV-positive subjects were very similar,
although in most cases the various RNA transcripts were de-
tected more frequently in the HIV-positive patients. This latter
finding is consistent with our previous observations which used
ISH to detect VZV DNA in normal and HIV-positive TG (12).
RNA was detected predominantly in neuronal nuclei in all
cases, which is also entirely consistent with our previous studies
of VZV DNA localization in human TG (12). There is now a
general consensus that latent VZV is located predominantly, if
not exclusively, in neurons (18).
In this study we detected VZV gene 63-encoded protein
predominantly in neurons in a minority (25%) of TG cases,
both HIV positive and normal. Interestingly, RNA for VZV
gene 63 was also the most frequently detected viral transcript
detected in this study. VZV gene 63 plays a transactivating and
transrepressing role in VZV gene regulation and is the ho-
molog of HSV gene ICP22 (10). While this is consistent with
some previous reports of both human (17) and rat (6) VZV
latency, nevertheless this finding appears not to be a frequent
event. It was necessary to screen large numbers of ganglia to
detect positive staining for this protein, and the significance of
its presence in the minority of ganglia is not known. Neverthe-
less, our data provide further support for a possibly significant
role of gene 63 in the latency process. In one case, gene 63-
encoded protein was detected without the corresponding
RNA. This presumably reflects technical factors such as assay
sensitivity or else a greater abundance of protein than of RNA,
which may have been degraded during the procedures. An-
other possibility is that VZV infection could have been focal
and happened to be in the region of antibody staining.
In an attempt to help interpret the ISH findings on the
ganglion sections, we carried out a series of experiments to
determine whether the pattern of VZV RNA detection in
explanted normal TG and DRG cultured soon after death was
different from that seen in the prefixed TG. Interestingly, we
found that the gene expression profiles were different in the
two groups, with a restricted pattern in the fixed ganglia con-
trasting with the detection of all VZV genes in the explanted
ganglia. In addition, the detection of some or all the VZV
transcripts in two subjects at very early time points indicates
that viral reactivation may have occurred very soon (within
14 h) after death of the individuals. Alternatively, this finding
could indicate that these two subjects may have had an active
VZV infection at the time of death, although this is probably
less likely. Our data showing increased VZV gene expression
with time in tissue culture differ from a previous study by Vafai
et al. (22), in which late VZV proteins were not detected with
monoclonal antibodies after 11 to 17 days in culture. The
reasons for this apparent discrepancy are unclear but may
relate to different sensitivities of the two methods used. Be-
cause of these marked differences in RNA expression in the
fixed TG compared with the explanted ganglia, we think it
highly likely that most, if not all, of the VZV transcripts de-
tected in the 35 fixed ganglia probably reflected true latent
gene expression. However, based on these and our previous
studies (12, 13), in which we have emphasized the difficulties
and potential pitfalls of applying molecular techniques to fixed
human nervous tissues, we have reached the conclusion that
complete certainty on the nature of VZV gene expression in
these fixed human TG and DRG is not possible to achieve.
While the data presented here certainly support the notion of
limited and specific VZV gene expression in latently infected
human ganglia, it is unlikely that the possibility of prior viral
reactivation at or soon after death of the individual can ever be
totally excluded. Detailed studies of VZV gene expression in
animal models of latent VZV infection will probably be re-
quired to circumvent this inherent uncertainty.
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